197853-31-9 Usage
Uses
Used in Urinary Tract Infections:
L 778,123 is used as an antibiotic for treating urinary tract infections caused by susceptible bacteria. Its broad-spectrum activity makes it effective against a variety of bacteria responsible for these infections.
Used in Gastrointestinal Infections:
L 778,123 is used as an antibiotic for treating gastrointestinal infections, including those caused by both Gram-positive and Gram-negative bacteria. Its ability to target a wide range of bacteria contributes to its effectiveness in managing these infections.
Used in Skin Infections:
L 778,123 is used as an antibiotic for treating skin infections caused by susceptible bacteria. Its broad-spectrum activity allows it to address various types of skin infections effectively.
Used in Antibacterial Research:
L 778,123 is used as a research compound for studying the mechanisms of action and potential clinical applications of nitrofuran antibiotics. Its unique properties and broad-spectrum activity make it a valuable tool in the development of new antimicrobial agents.
Used in Drug Development:
L 778,123 is used as a lead compound in the development of new antibiotics with improved efficacy, safety, and resistance profiles. Its broad-spectrum activity and potential for clinical applications make it a promising candidate for further research and development in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 197853-31-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,7,8,5 and 3 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 197853-31:
(8*1)+(7*9)+(6*7)+(5*8)+(4*5)+(3*3)+(2*3)+(1*1)=189
189 % 10 = 9
So 197853-31-9 is a valid CAS Registry Number.
197853-31-9Relevant academic research and scientific papers
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase
Dinsmore, Christopher J,Bergman, Jeffrey M,Wei, Donna D,Zartman,Davide, Joseph P,Greenberg, Ian B,Liu, Dongming,O'Neill, Timothy J,Gibbs, Jackson B,Koblan, Kenneth S,Kohl, Nancy E,Lobell, Robert B,Chen, I-Wu,McLoughlin, Debra A,Olah, Timothy V,Graham, Samuel L,Hartman, George D,Williams, Theresa M
, p. 537 - 540 (2007/10/03)
The evaluation of SAR associated with the insertion of carbonyl groups at various positions of N-arylpiperazinone farnesyltransferase inhibitors is described herein. 1-Aryl-2,3-diketopiperazine derivatives exhibited the best balance of potency and pharmac
INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
-
, (2008/06/13)
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent
